Ablenio Biosciences LLC.

We are pioneers in the field of complement-mediated rare diseases. Our scientists are focused on discovering novel therapies for rare diseases in which the complement alternative pathway is a key driver of pathogenesis. Unlike C5 blockers in the complement space, we focus on therapies that can intervene upstream in the complement system, selectively targeting the underlying pathway of each disease in question. This way, one drug can target many diseases. We are continuously motivated by the needs of patients as we discover unique therapies for rare diseases. Every rare disease is unique, but their treatment may be similar to others if they fall under complement-mediated diseases to be treated by the same drug. Such opportunities are extremely exciting for innovators and drug developers.